A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample
© Eidukevicius et al; licensee BioMed Central Ltd. 2005
Received: 28 December 2004
Accepted: 22 September 2005
Published: 22 September 2005
Presently available flow cytometric methods of bromodeoxyuridine (BrdUrd) labelling do not provide information on the cell cycle time (TC) and the growth fraction (GF). In this paper, we describe a novel and simple method to estimate TC and GF from flow cytometric analysis of a single tumour sample after BrdUrd labelling.
The proposed method is based on two assumptions: (1) the number of labelled cells traversing the cell cycle per unit time is constant and (2) the total number of labelled cells is constant throughout the cycle, provided that cells produced after division are excluded. The total numbers of labelled divided G1 cells, labelled divided S cells, labelled undivided S cells, and labelled undivided G2 cells were obtained for DNA histograms of BrdUrd-positive cells in a collected sample. These cell numbers were used to write equations to determine the durations of cell cycle phases, TC and GF. To illustrate the application of the proposed formulae, cell cycle kinetic parameters were analysed in solid SL2 tumours growing in DBA/2 mice and in human T-leukaemia Jurkat cells in culture.
The suitability of the proposed method for estimating durations of the cell cycle phases, TC and GF was demonstrated. TC in SL2 tumours was found to be relatively constant at 4 and 10 days after tumour implantation (20.3 ± 1.1 h and 21.6 ± 0.9 h, respectively). GF in tumours at day 10 was lower than GF at day 4 (54.2 ± 7.7% vs. 79.2 ± 5.9%, p = 0.0003). Approximate values of TC and GF of cultured Jurkat cells were 23.9 h and 79.3%, respectively.
The proposed method is relatively simple and permits estimation of the cell cycle parameters, including TC and GF, from a single tumour sample after labelling with BrdUrd. We have shown that this method may be useful in preclinical studies, allowing estimation of changes in GF during growth of murine tumours. Experiments with human Jurkat cells suggest that the proposed method might also prove suitable for measurement of cell kinetics in human tumours. Development of suitable software enabling more objective interpretation of the DNA profile in this method would be desirable.
Uncontrolled proliferation is regarded as one of the most important traits of malignancy. Therefore, a considerable effort has been directed to the evaluation of the parameters of cell kinetics in tumours. A significant improvement in cell kinetic studies was achieved by the introduction of the technique of flow cytometric analysis of cells labelled with bromodeoxyuridine (BrdUrd) and the relative movement (RM) method . The RM method allows estimation of the duration of S phase (TS) and the labelling index (LI) from a single sample. From these parameters, the potential doubling time (Tpot) can be calculated. Tpot is defined as the time to double the number of proliferating cells in the absence of cell loss . This derived cell kinetic parameter has been postulated to be a predictor of a tumour's proliferative capability and has been widely studied in clinic in an attempt to find its prognostic significance and the potential value in predicting treatment outcome . However, more recent evidence has not confirmed the existence of association between Tpot and disease outcome measures, whereas information on clinical significance of LI and TS remains ambiguous [3–5]. Therefore, new methods of evaluating cell kinetics in tumours are required.
Cell production rate is determined by the cell cycle time (TC), i.e. the time interval between cell divisions, and the growth fraction (GF), i.e. the proportion of cells engaged in the cell cycle. Thus, TC and GF can be regarded as the most important parameters in evaluating cell production in tumours. However, neither the original RM method  nor its more recent modification  provide enough data to calculate the duration of all cell cycle phases, consequently the duration of the whole cycle, and GF of a tumour.
TC and GF can be estimated by calculating the percent BrdUrd labelling in tumour samples vs. time after injection of BrdUrd. However, the disadvantage of this method is that subsequent tumour samples have to be taken at intervals during several days after the administration of BrdUrd . This method does not allow a measurement of cell kinetics in an individual tumour at a particular time point and is useless in a clinical setting.
Currently, proliferation-related antigen Ki-67 is widely used to measure GF in tumours and normal tissues. The Ki-67 antigen is considered to be present in the nuclei of cells in the G1, S and G2 phases of the cell cycle as well as in mitosis, but not in quiescent cells (cells in G0) . Although the relationship between Ki-67 protein expression and cell proliferation is established, there is some evidence that expression of Ki-67 antigen may be minimal in late G1 and early S phase cells . The accessibility of Ki-67 epitopes may vary during the cell cycle . In addition, not all cells containing Ki-67 antigen may be actively proliferating . Thus, detection of proliferative markers (such as Ki-67) may not correspond in every case to the theoretically defined term of GF. Obviously, determination of proliferative markers does not provide information about TC.
In this paper, we describe a novel and simple method to estimate TC and GF from flow cytometric analysis of a single tumour sample after BrdUrd labelling.
Mice and tumours
Female DBA/2 mice at the age of 8–12 weeks were obtained from the local breeding facility at the Institute of Immunology, Vilnius, Lithuania. SL2, a spontaneously arisen DBA/2 – derived lymphoma was maintained by weekly intraperitoneal passage in DBA/2 mice. Solid SL2 tumours for cell proliferation analysis were induced by subcutaneous injection of 107 SL2 cells on the chest of mice and analysed after 4 and 10 days.
Experimental research on animals has been conducted according to recommendations of the Lithuanian Ethics Committee for the Laboratory Animal Use.
Human acute T-cell leukaemia Jurkat cells were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum. The cultures were incubated at 37°C in a humidified atmosphere with 5% CO2.
The mice were injected i.p. with 1 ml of 2 mg/ml BrdUrd (5-bromo-2'-deoxyuridine, Sigma, St Louis, MO, USA) solution in physiological saline. The half-life of BrdUrd in rodent blood is only about 15 min. Therefore, a single i.p. injection acts as a pulse label . At 10 h after BrdUrd injection the tumours were dissected and cut into slices of about 1 mm thickness. To avoid sampling errors, several slices were cut both from central and peripheral parts of a tumour. Tumour slices were fixed in 70% ethanol, and stored at +4°C for one or two days until staining.
For in vitro labelling of Jurkat cells, BrdUrd was dissolved in phosphate-buffered saline (PBS) and added to culture medium at a final concentration of 10 μM. After incubation for 30 min at 37°C, the cells were rinsed twice with RPMI 1640 medium and the cultures further incubated at 37°C. Samples for analysis were taken at 8, 10, 12 and 16 h after the BrdUrd pulse, the cells were washed with PBS and fixed in 70% ice-cold ethanol.
Flow cytometric staining and measurement
Slices of solid SL2 tumours were cut in fragments of about 1 mm3 and incubated in 0.4 mg/ml pepsin solution in 0.1 N HCl at 37°C with continuous agitation to produce a nuclear suspension. Isolation of nuclei was revealed by microscopic observation after 30 to 60 min of incubation. The nuclear suspension was filtered through a 48 μm nylon mesh. Nuclear suspensions of SL2 cells and suspensions of fixed Jurkat cells were washed and incubated in 2 N HCl for 30 min at room temperature for DNA denaturation. The acid solution was then neutralised with 0.1 M Na2B4O7 (pH 8.5) and the nuclear or cell suspensions were washed twice in PBS. Fifty μl of PBS containing 0.5% Tween 20 and 20 μl of FITC-conjugated mouse anti-BrdUrd monoclonal antibody (Becton Dickinson, Heidelberg, Germany) was added to the pellet containing 106 nuclei and incubated for 30 min at room temperature in the dark. After washing twice in PBS, 1 ml of a solution containing 5 mg/l propidium iodide (Sigma, St Louis, MO, USA) in PBS was added to the pellet and incubated for 30 min at 37°C in the dark.
The cellular DNA content and the amount of incorporated BrdUrd were simultaneously measured using a FACSort flow cytometer (Becton Dickinson, Heidelberg, Germany). Green fluorescent light emission (FITC = BrdUrd incorporation) was collected in the FL1 detector and red fluorescence (propidium iodide = DNA content) was collected in FL2 (for SL2 cells) or FL3 (for Jurkat cells) detector. Data from 15,000 nuclei per sample were acquired as dot plots of BrdUrd labelling vs. DNA content using LYSYS II software (Becton Dickinson, Heidelberg, Germany). Doublets were excluded by using the doublet discrimination mode. WinMDI version 2.8 software was used to analyse the acquired data.
Mathematical formulae for estimation of duration of cell cycle phases and GF in BrdUrd-labelled tumours
We propose that the total number of cells Sl labelled during the BrdUrd pulse can be estimated after any time interval shorter than the duration of the cell cycle as
The proposed method requires that considerable proportions of cells be found in Slu and Sld compartments. Slu and Sld compartments can be distinguished in the DNA histogram of BrdUrd-positive cells, provided that the time interval t after the BrdUrd pulse is shorter than the duration of the S phase, but sufficient for the labelled cells to re-enter a new S phase, i.e. if + < t < TS ( , and TS are durations of G2, G1 and S phases of the cell cycle, respectively). Sld compartment was separated from Slu compartment by the channel corresponding to the lowest number of events (Figure 2C).
The number of labelled cells traversing S phase per unit time can be estimated as
The number of labelled cells traversing G2 phase, mitosis, G1 phase and re-entering S phase per unit time can be estimated as
The labelled cells begin to enter G1 phase after time and the number of cells traversing G1 phase and re-entering S phase per unit time can be estimated as
Estimation of durations of cell cycle phases in the proposed method is based on the assumption that the number of labelled cells traversing the cell cycle per unit time is constant. One of the models illustrating this assumption is the rectangular age distribution of proliferating cells described by Steel . In this case, ν1 = ν2 = ν3 = ν4 and
GF can be estimated using the classical formula reported by Steel :
where LI is the labelling index of the whole population and LIP is the labelling index of proliferating cells. If the number of labelled cells traversing the cell cycle per unit time is constant, we have
where TC is the duration of the cell cycle (TC = + TS + ). The LI can be calculated by the formula proposed by Johansson et al. :
where nt is the total number of BrdUrd-positive and BrdUrd-negative cells measured per sample, G2 is the total number of G2 phase cells and G2 ul is the number of unlabelled G2 cells. In the proposed method, t < TS and G2 ul is negligible. Thus, the total number of G2 phase cells is approximately equal to G2 lu.
Formulae for estimation of durations of cell cycle phases based on a decreasing exponential cell age distribution hypothesis are presented in the Additional file 1.
In addition to using the proposed formulae, TS values were estimated also using the classical RM method , here referred to as RM (linear), and the more recently proposed RM method, based on a cubic fit to the RM , here referred to as RM (cubic). The latter method also allows calculation of . Using the RM (linear) method, the relative mean DNA content RM(t) of the moving cohort of BrdUrd-labelled cells in relation to that of G1 and G2 cells, was calculated using the formula
Using the RM (cubic) method, TS was calculated from the equation
In this equation, ν is defined as
where flu(t) and fld(t) are fractions of labelled undivided and labelled divided cells, respectively, at post-labelling time t. In our case, flu(t) is the fraction of Slu and G2 lu cells, and fld(t) – the fraction of G1 ld and Sld cells, respectively, in the total number of cells nt measured per sample.
An assumed exponential growth rate c was estimated as
Pearson's correlation coefficient was used to determine the correlation between the TS or values obtained using the proposed method and the RM approach. Differences between the GF values at day 4 and day 10 were analysed by the Wilcoxon rank sums test.
Estimation of durations of cell cycle phases in murine SL2 tumours using the proposed method and the RM methods *
4 days (n = 10)
5.1 ± 0.4
12.6 ± 1.0
2.6 ± 0.5
20.3 ± 1.1
14.1 ± 1.5
14.8 ± 1.6
0.7 ± 0.4
10 days (n = 9)
5.4 ± 0.5
12.9 ± 0.6
3.3 ± 0.5
21.6 ± 0.9
14.4 ± 1.1
15.8 ± 3.3
1.4 ± 0.6
Estimation of durations of cell cycle phases and GF in Jurkat cell line using the proposed method at different times of measurement *
Hours after BrdUrd labelling
Estimates of durations of cell cycle phases based on rectangular age distribution hypothesis and corresponding estimates obtained by calculations based on a decreasing exponential cell age distribution hypothesis are compared in supplementary Table 1 [see Additional file 1]. Numerical examples illustrating that the estimates of durations of cell cycle phases are not very sensitive to erroneous setting (+/-5%) of regions of interest in the DNA-BrdUrd plots are presented in supplementary Table 2 [see Additional file 2].
The proposed method is based on two assumptions. The first assumption, i.e., the labelled cell mortality or exit from the cell cycle during the period of measurement is negligible, can be regarded as reasonably simple and generally acceptable. On the other hand, it is quite difficult to obtain reliable estimates of cell death rates in bivariate BrdUrd/DNA cytometry. A method for estimating the rate of cell death in G2/M phase of exponentially growing cell populations has only recently been published .
The second assumption is that the number of labelled cells traversing the cell cycle per unit time is constant. Although rather simplistic, this assumption does not appear to induce a great extent of error, as illustrated by corresponding estimates obtained by calculations based on a decreasing exponential cell age distribution hypothesis.
Our results illustrate, that the proposed method can be successfully used to obtain kinetic estimates of the cell cycle and GF in a murine tumour in vivo and in human tumour cells in vitro. The finding of a decrease in GF with the "age" of murine tumours shows that information retrieved with the proposed method may be biologically relevant. A good correlation was found between the TS values of SL2 tumours obtained using our proposed method and the generally accepted RM (linear) or RM (cubic) methods. The values of SL2 tumours obtained with the proposed method correlated with the values obtained with the RM (cubic) method.
The TS values obtained with the proposed method had a narrower spread (11.6 to 14.7 h) compared to the TS values in the same tumours obtained with the RM (linear) and the RM (cubic) method (12.6 to 17.6 h and 13.5 to 18.9 h, respectively). Thus, the TS values of SL2 tumours obtained with the proposed method are more compatible with the notion that TS may be a species-specific constant . The TS values obtained using the proposed method were slightly lower than those obtained using the RM methods. This difference can be explained by the fact that in the RM approach, the moving cohort of BrdUrd-labelled cells includes some G2 cells, which actually are not moving in the histogram. Thus, the RM of the cohort of BrdUrd-labelled cells is slower than actual traversing of cells through the S phase. Therefore, we think that our proposed formulae provide more accurate estimation of TS.
Similarly to other methods of analysis of cell kinetics using DNA profiles, the proposed method is subject to errors of profile interpretation. Using a fitting programme to extract more accurate data would be preferable. To our knowledge, however, currently available fitting programmes (including ModFit LT™, version 3.1) do not allow the separation of Slu and Sld compartments, the essential procedure in the proposed method. Thus, none of the currently available software can by applied for analysis of the DNA profile in a way required for the proposed method. On the other hand, the identification of a single channel with the minimum event count to separate Slu and Sld compartments was feasible in all DNA histograms analysed and, therefore, can be regarded as quite robust procedure.
Both the RM approach and the proposed method entail the problem of separation of diploid tumour cells from normal intratumoural cells. In the proposed method, admixture of normal cells does not affect the determination of TC, because this parameter is estimated using only BrdUrd-labelled cells, and proliferation of normal intratumoural cells is usually negligible. However, the proposed method may underestimate GF in diploid tumours, if procedures to separate normal cells from tumour cells are not used. The possible solutions to tackle this problem have been summarized by Antognoni P et al.  and are mainly based on using cytokeratin markers to separate epithelial tumour cells from intratumoural inflammatory cells and fibroblasts. In addition, it is recommended to present cell kinetic data from diploid and aneuploid tumours separately . SL2 was proved to be an aneuploid (nearly tetraploid) tumour with the DNA index of 1.8 (data not shown). Thus, admixture of normal cells in our analysis can be ruled out.
In experiments with SL2 tumour, PI fluorescence was collected in the FL2 detector and compensation for the spectral overlap with FITC fluorescence was used. Generally, however, it is recommended to use FL3 (as done in experiments with Jurkat cells) rather than FL2 to overcome any crossover with the FITC in FL1 . Running the samples at a higher FL3 voltage such that more of the scale is used would facilitate detection of hypodiploid DNA peaks.
In the RM approach, BrdUrd is injected usually 4 to 8 h prior to biopsy or surgical removal of a tumour . The proposed method requires that considerable proportions of cells be found in each of the four compartments to be analysed (Slu, G2 lu, G1 ld, and Sld). This condition is fulfilled only if the time interval from the BrdUrd pulse to the time of measurement is longer than duration of G2 and G1 phases but still shorter than duration of S phase. Obviously, this cannot be assured in advance. Thus, the proposed method has to be tailored for a particular tumour type and the optimal time of measurement has to be found by trial and error. As an example of this trial and error procedure, the finding of an optimal time for measurement of cell kinetics in Jurkat cells is described in this paper.
Measurements with Jurkat cells also show, that the proposed method may be sensitive to intercell variability in phase transit times. If the time of measurement is too short and only the fastest cells enter Sld compartment (e.g. 10 h in case of Jurkat cells), the duration of G1 phase may be underestimated. On the other hand, if the time of measurement is too long and only the slowest cells remain in the Slu compartment (e.g. 16 h in case of Jurkat cells), the duration of S and other cell cycle phases may be overestimated. Thus, the time for measurement of cell kinetics with the proposed method has to be selected carefully. To minimize the effect of intercell variability in phase transit times, it is advisable to use the same time interval from the BrdUrd pulse to the time of measurement in all samples to be compared.
Measurements with cultured Jurkat cells presented in this paper suggest that the proposed method might be also suitable for studies on human tumours. It seems that the suitability of the proposed method for clinical studies could only be compromised if the G1 phase in human tumours in vivo was very long. Obviously, this can only be determined by testing the proposed method in clinical studies after infusion of BrdUrd to patients.
The proposed method is relatively simple and permits estimation of cell cycle parameters, including TC and GF, from a single tumour sample after labelling with BrdUrd. We have shown that this method may be useful in preclinical studies, allowing estimation of changes in GF during growth of murine tumours. Experiments with human Jurkat cells suggest that the proposed method might also prove suitable for measurement of cell kinetics in human tumours. Development of suitable software enabling more objective interpretation of the DNA profile in this method would be desirable.
- Begg AC, McNally NJ, Shrieve DC, Karcher H: A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry. 1985, 6: 620-626. 10.1002/cyto.990060618.View ArticlePubMedGoogle Scholar
- Antognoni P, Terry NHA, Richetti A, Luraghi R, Tordiglione M, Danova M: The predictive role of flow cytometry-derived tumor potential doubling time (Tpot) in radiotherapy: open questions and future perspectives. Int J Oncol. 1998, 12: 245-256.PubMedGoogle Scholar
- Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Rutgers D, Wilson GD: The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol. 1999, 50: 13-23. 10.1016/S0167-8140(98)00147-9.View ArticlePubMedGoogle Scholar
- Haustermans K, Fowler JF: Is there a future for cell kinetic measurements using IdUrd or BdUrd?. Int J Radiat Oncol Biol Phys. 2001, 49: 505-511. 10.1016/S0360-3016(00)01506-6.View ArticlePubMedGoogle Scholar
- Dobrowsky W, Dobrowsky E, Wilson GD: In vivo cell kinetic measurements in a randomized trial of continuous hyperfractionated accelerated radiotherapy with or without mitomycin C in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003, 55: 576-582. 10.1016/S0360-3016(02)04121-4.View ArticlePubMedGoogle Scholar
- White RA, Meistrich ML, Pollack A, Terry NH: Simultaneous estimation of TG2+M, TS, and Tpot using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry. Cytometry. 2000, 41: 1-8. 10.1002/1097-0320(20000901)41:1<1::AID-CYTO1>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Zätterström UK, Johansson M, Källén A, Baldetorp B, Oredsson S, Wennerberg J, Killander D: Comparison of BrdUrd and [3H]TdR incorporation to estimate cell proliferation, cell loss, and potential doubling time in tumor xenografts. Cytometry. 1992, 13: 872-879. 10.1002/cyto.990130810.View ArticlePubMedGoogle Scholar
- Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182: 311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Bruno S, Darzynkiewicz Z: Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992, 25: 31-40.View ArticlePubMedGoogle Scholar
- Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, Togni R, Dalla Palma P, Doglioni C: Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol. 1994, 102: 171-175.View ArticlePubMedGoogle Scholar
- Van Oijen MG, Medema RH, Slootweg PJ, Rijksen G: Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol. 1998, 110: 24-31.View ArticlePubMedGoogle Scholar
- Wilson GD: Analysis of DNA – measurement of cell kinetics by the bromodeoxyuridine/anti-bromodeoxyuridine method. Flow Cytometry: A Practical Approach. Edited by: Ormerod MG. 2000, New York: Oxford University Press, 159-177. 3Google Scholar
- Johansson MC, Johansson R, Baldetorp B, Oredsson SM: Comparison of different labelling index formulae used on bromodeoxyuridine-flow cytometry data. Cytometry. 1998, 32: 233-240. 10.1002/(SICI)1097-0320(19980701)32:3<233::AID-CYTO10>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Steel GG: Growth kinetics of tumours. 1977, Oxford: Oxford University PressGoogle Scholar
- White RA, Asmuth DM, Lu Y, Wang N, Li XD, Reece L, Pollard RB, Nokta M, Leary JF, Terry NH: Estimating cell death in G(2)M using bivariate BrdUrd/DNA flow cytometry. Cytometry. 2005, 66: 32-40. 10.1002/cyto.a.20147.View ArticlePubMedGoogle Scholar
- Rew DA, Wilson GD: Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol. 2000, 26: 405-417. 10.1053/ejso.1999.0907.View ArticlePubMedGoogle Scholar
- Terry NH, Peters LJ: The predictive value of tumor-cell kinetic parameters in radiotherapy: considerations regarding data production and analysis. J Clin Oncol. 1995, 13: 1833-1836.PubMedGoogle Scholar
- Baisch H, Otto U, Hatje U, Fack H: Heterogeneous cell kinetics in tumors analyzed with a simulation model for bromodeoxyuridine single and multiple labeling. Cytometry. 1995, 21: 52-61. 10.1002/cyto.990210111.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/122/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.